Related Experiment Video
Updated: Jun 27, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Defining the In Vivo Role of mTORC1 in Thyrocytes by Studying the TSC2 Conditional Knockout Mouse Model
Camila Ludke Rossetti1, Bruna Lourençoni Alves1,2, Flavia Leticia Martins Peçanha1
1Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, Florida, USA.
Abstract:
Background: The thyroid gland is susceptible to abnormal epithelial cell growth, often resulting in thyroid dysfunction. The serine-threonine protein kinase mechanistic target of rapamycin (mTOR) regulates cellular metabolism, proliferation, and growth through two different protein complexes, mTORC1 and mTORC2. The PI3K-Akt-mTORC1 pathway's overactivity is well associated with heightened aggressiveness in thyroid cancer, but recent studies indicate the involvement of mTORC2 as well. Methods: To elucidate mTORC1's role in thyrocytes, we developed a novel mouse model with mTORC1 gain of function in thyrocytes by deleting tuberous sclerosis complex 2 (TSC2), an intracellular inhibitor of mTORC1. Results: The resulting TPO-TSC2KO mice exhibited a 70-80% reduction in TSC2 levels, leading to a sixfold increase in mTORC1 activity. Thyroid glands of both male and female TPO-TSC2KO mice displayed rapid enlargement and continued growth throughout life, with larger follicles and increased colloid and epithelium areas. We observed elevated thyrocyte proliferation as indicated by Ki67 staining and elevated cyclin D3 expression in the TPO-TSC2KO mice. mTORC1 activation resulted in a progressive downregulation of key genes involved in thyroid hormone biosynthesis, including thyroglobulin (Tg), thyroid peroxidase (Tpo), and sodium-iodide symporter (Nis), while Tff1, Pax8, and Mct8 mRNA levels remained unaffected. NIS protein expression was also diminished in TPO-TSC2KO mice. Treatment with the mTORC1 inhibitor rapamycin prevented thyroid mass expansion and restored the gene expression alterations in TPO-TSC2KO mice. Although total thyroxine (T4), total triiodothyronine (T3), and TSH plasma levels were normal at 2 months of age, a slight decrease in T4 and an increase in TSH levels were observed at 6 and 12 months of age while T3 remained similar in TPO-TSC2KO compared with littermate control mice. Conclusions: Our thyrocyte-specific mouse model reveals that mTORC1 activation inhibits thyroid hormone (TH) biosynthesis, suppresses thyrocyte gene expression, and promotes growth and proliferation.
Insights
Mechanistic target of rapamycin complex 1 (mTORC1) activation in thyroid cells drives thyroid gland growth and proliferation. This activation inhibits thyroid hormone biosynthesis and gene expression, effects reversed by rapamycin treatment.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Thyroid dysfunction arises from abnormal epithelial cell growth.
- The mechanistic target of rapamycin (mTOR) pathway, including mTORC1 and mTORC2, regulates cell growth and metabolism.
- Overactive PI3K-Akt-mTORC1 signaling is linked to aggressive thyroid cancer.
Purpose of the Study:
- To investigate the specific role of mTORC1 in thyrocytes.
- To develop and characterize a novel mouse model with gain-of-function mTORC1 in thyrocytes.
Main Methods:
- Created a thyrocyte-specific mouse model (TPO-TSC2) by deleting TSC2, an mTORC1 inhibitor.
- Assessed thyroid gland size, thyrocyte proliferation (Ki67, cyclin D3), gene expression (Tg, Tpo, Nis), and protein levels (NIS).
- Administered the mTORC1 inhibitor rapamycin to evaluate its effects on thyroid mass and gene expression.
Main Results:
- TPO-TSC2 mice showed significantly reduced TSC2 and increased mTORC1 activity, leading to thyroid enlargement and increased thyrocyte proliferation.
- mTORC1 activation suppressed key thyroid hormone biosynthesis genes (Tg, Tpo, Nis) and NIS protein expression.
- Rapamycin treatment normalized thyroid mass and gene expression in TPO-TSC2 mice.
- While hormone levels were initially normal, TPO-TSC2 mice developed decreased T4 and increased TSH by 12 months.
Conclusions:
- Thyrocyte-specific mTORC1 activation promotes thyroid growth and proliferation.
- mTORC1 signaling inhibits thyroid hormone biosynthesis and thyrocyte-specific gene expression.
- Targeting mTORC1 with rapamycin can counteract these effects, suggesting therapeutic potential.
More Related Videos
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...